Fig. 3From: Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case reportRise in creatinine in relation to cycle 1 and cycle 2 (C1 and C2, respectively) of pembrolizumabBack to article page